You are viewing a preview of...

Vaccines Against Malaria

A novel malaria vaccine composition that is fully characterized with significant clinical efficacy demonstrated in humans

Background

Malaria, caused by the parasite Plasmodium falciparum, kills hundreds of thousands of children annually. Emergence of multi-drug-resistant strains indicates an urgent need for an efficacious vaccine for those living in malaria-endemic areas, as well as for those who travel to these areas such as tourists and troops.

Technology Overview

Scientists from the Walter Reed Army Institute of Research (WRAIR) and HJF and have developed a novel malaria vaccine composition that contains a novel Plasmodium falciparum circumsporozoite protein (CSP) immunogen FMP013 formulated with the patented adjuvant ALFQ. FMP013/ALFQ had high immunogenicity in animals including mice and rhesus macaques and was selected for further clinical studies in humans.

The results from the Phase I clinical study have shown that

Log in or create a free account to continue reading